October 8, 2011

The Impact of Conversion From Prograf to Generic Tacrolimus in Liver and Kidney Transplant Recipients With Stable Graft Function

.   .   

Most immunosuppressive agents used in transplantation will become available as generics in the next few years. This might significantly reduce the costs of transplantation, but there is concern that the pharmacokinetics of generic formulations will not be the same as the brand-name drug, resulting in either inadequate immunosuppression or excessive toxicity. In this paper, stable kidney and liver transplant recipients on Prograf (tacrolimus) were converted to a generic formulation. Renal and liver function remained stable after conversion, and there were no episodes of acute rejection, but almost 40% of patients needed an adjustment in their drug dose. Also, this was a non-randomized, non-placebo-controlled study, with short follow-up, and assessing only a single generic formulation.

Related Articles:

Renal Transplantation
  • Ojpjpo

    Could this be anything but drug company backed propaganda.  Shame on you american journal of transplantation for publishing this.